Thrombotic thrombocytopenic purpura or cobalamin deficiency? A case report and review

Neill Tuten1,*, Charles Bennett2 and William Babcock2
1Department of Medicine, University of South Carolina, USA
2WJB Dorn VA Medical Center, Columbia, SC, USA

Abstract

Introduction: The classic presentation of cobalamin deficiency consists of a macrocytic anemia with or without neurologic manifestations. A common cause of cobalamin deficiency is pernicious anemia, an autoimmune condition in which anti-intrinsic factor antibodies are present. We present a case of pernicious anemia masked by features consistent with thrombotic thrombocytopenic purpura, as well as a review of similar cases in the literature.

Case presentation: A 31 year old male presented to the Emergency Department with symptomatic anemia and altered mental status. Laboratory data was significant for microangiopathic hemolytic anemia and thrombocytopenia. A clinical diagnosis of thrombotic thrombocytopenic purpura was made and plasma exchange was initiated. Due to the lack of improvement with plasma exchange, additional laboratory studies were obtained which showed cobalamin deficiency, intrinsic factor antibodies, and ADAMTS13 levels within normal limits. The patient’s clinical and laboratory status improved with parenteral cobalamin replacement and discontinuation of plasma exchange.

Discussion: Severe cobalamin deficiency can present as a severe microangiopathic hemolytic anemia that responds rapidly to cobalamin replacement. Key differentiating considerations from thrombotic thrombocytopenic purpura are markedly elevated lactate dehydrogenase, low reticulocyte count, six-lobed polymorphonuclear white blood cells on the peripheral blood smear, and markedly low serum cobalamin.

Correspondence to: Neill Tuten, MD, Assistant Professor, Department of Medicine, 1 Medical Center Drive, PO Box 9156, Morgantown, WV 26506, West Virginia University, Tel: 803-300-2120; Fax: 304-293-2710; E-mail: neilltuten@gmail.com

Key words: pseudo-TMA, cobalamin (B12) deficiency, pernicious anemia

Received: July 15, 2015; Accepted: August 14, 2015; Published: August 17, 2015
rose with daily Cbl supplements. Subsequently, ADAMTS13 activity level was found not to be low.

Additional history obtained from family members indicated that the patient had had a cognitive deficit and personality issues for several years. Over a period of 3-4 days, decreased irritability and akathisias were noted, and all hematological abnormalities improved with continued Cbl replacement.

At follow-up appointment with a hematologist six weeks after discharge, the patient was noted to have continued altered mental ability although this had improved since hospitalization. Laboratory data were: hemoglobin 12.3 g/dL, hematocrit 38%, MCV 76.6 fL, platelet count 189 K/cmm, LDH 192 U/L, vitamin B12 357 pg/mL, reticulocyte count 1.28%, total bilirubin 0.2 mg/dL, and indirect bilirubin 0.1 mg/dL.

At follow-up appointment 4 months after discharge, the patient’s mental acuity remained unchanged. Laboratory data were: hemoglobin 14 g/dL, hematocrit 42.8%, MCV 77.1 fL, platelet count 186 K/cmm, Cbl 669 pg/mL.

Eight-month follow-up was notable for remarkable improvement in mental status, as evidenced by the patient’s answering of questions more appropriately. Laboratory data at eight-month follow-up: hemoglobin 14.6 g/dL, hematocrit 44.4%, MCV 83.2 fL, and platelet count 166 K/cmm.

Discussion

Red blood cell production is dependent on Cbl. When Cbl is deficient, red blood cell membrane rigidity increases and erythrocyte deformability decreases [2]. These changes ultimately result in cell lysis, causing hemolytic anemia, and elevation of serum LDH levels [3]. LDH levels appear to be markedly higher among persons with MAHA due to Cbl deficiency versus TTP [1,4]. Cbl deficiency also causes elevated homocysteine levels, which leads to endothelial dysfunction and results in fragmentation of erythrocytes to schistocytes [5].

In 2011, Tadakamalla et al. described a patient with PA who was initially diagnosed with TTP based on hemolysis, thrombocytopenia and numerous schistocytes being identified in the initial peripheral blood smear. After four days of plasmapheresis, thrombocytopenia worsened. On re-evaluation, serum Cbl levels were low. The patient improved with intra-muscular Cbl treatment initiated after laboratory studies identified anti-IF antibodies and elevated serum gastrin levels, and an endoscopy identified atrophic gastritis [6].

In 2008, Dalsania et al. reported a patient who was also initially diagnosed with TTP based on severe thrombocytopenia that persisted
following daily plasmapheresis. Additional evaluation led to a clinical diagnosis of pseudo-TMA secondary to PA [4]. Two similar cases of pseudo-TMA were reported previously in 2006 and 2003 [7,8].

In 2013, Noël et al. aimed to identify clinical and laboratory factors that could easily distinguish between TTP and pseudo-TMA related to Cbl deficiency. This retrospective study compared seven patients with pseudo-TMA and six patients with TTP. Pseudo-TMA patients had higher mean lactate dehydrogenase (LDH) levels (7310 vs. 1460 IU/l, \(P=0.01\)), higher mean platelet counts (73 vs. 12.5 x 10^9/l, \(P=0.0023\)), lower mean reticulocyte count (13.1 vs. 265.5 x 10^9/l, \(P=0.0012\)) and lower mean neutrophil count (1.3 vs. 5.1 x 10^9/l, \(P=0.0023\)) at presentation. They concluded that a very high LDH level and a low reticulocyte count should prompt screening for Cbl deficiency among persons who present with a clinical diagnosis of possible TTP [1].

Physicians should screen for Cbl deficiency when persons with a working diagnosis of TTP present with these laboratory findings. In contrast, acute renal failure and acute altered mental status point to TTP rather than pseudo-TMA. Our patient presented with a more chronic course of confusion and agitation rather than acute neurologic changes. Neurologic deficits persisted at six weeks after discharge, suggesting some degree of permanent neurological impairment due to long-standing Cbl deficiency. At eight month follow-up, our patient’s mental status was remarkably improved.

Atypical presentations of common disorders can very easily be mistaken for other diseases, as in our case of pseudo-TMA secondary to Cbl deficiency mimicking TTP. Although severe Cbl deficiency is unusual, it still occurs. It is therefore prudent for clinicians to consider pseudo-TMA due to severe Cbl deficiency in the differential diagnosis for patients who present with a TTP-like picture with hemolytic anemia, thrombocytopenia, and schistocytosis.

We conclude that Cbl replacement may yield rapid clinical and hematological improvement among patients with severe Cbl deficiency who present with pseudo-TMA. Rapid diagnosis of pseudo-TMA due to severe Cbl deficiency and initiation of parenteral Cbl replacement may prevent unnecessary and expensive diagnostic workups and prolonged plasma exchange treatments.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
NT was the primary author composing, originally documenting the patients care as an inpatient and composing the case report. CB and WB are the attending hematologists who follow the patient; they contributed information regarding the progress of the patient after leaving hospital and contributed to the editing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to acknowledge the contributions of Dr. Nevene Andraws to this case. She is the pathologist who provided the peripheral smear images. She has no relevant financial disclosure.

References

Copyright: ©2015 Tuten N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.